BlackRock Updates CYTOKINETICS Stake in SC 13G/A Amendment 5
Ticker: CYTK · Form: SC 13G/A · Filed: Jan 22, 2024 · CIK: 1061983
| Field | Detail |
|---|---|
| Company | Cytokinetics Inc (CYTK) |
| Form Type | SC 13G/A |
| Filed Date | Jan 22, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investing
TL;DR
**BlackRock just updated its stake in CYTOKINETICS, showing continued institutional interest.**
AI Summary
BlackRock, Inc. filed an amended SC 13G/A on January 22, 2024, indicating its ownership of Common Stock in CYTOKINETICS INC as of December 31, 2023. This filing, Amendment No. 5, updates their previous disclosures regarding their stake in the pharmaceutical company. For investors, this matters because BlackRock is a major institutional investor, and changes in their reported holdings can signal their confidence (or lack thereof) in the company's future prospects, potentially influencing other investors.
Why It Matters
This filing shows BlackRock's continued, albeit updated, significant ownership in CYTOKINETICS INC, which can be seen as a vote of confidence from a major institutional investor.
Risk Assessment
Risk Level: low — This filing is a routine update from a large institutional investor and does not indicate any immediate significant risk or opportunity.
Analyst Insight
Investors should note BlackRock's continued presence as a significant shareholder in CYTOKINETICS INC, but this filing alone doesn't provide enough detail to warrant a specific investment action beyond acknowledging institutional interest.
Key Players & Entities
- BlackRock, Inc. (company) — the reporting person and institutional investor
- CYTOKINETICS INC (company) — the subject company whose securities are being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 22, 2024 (date) — the filing date of the SC 13G/A
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, as stated in the 'FORM TYPE: SC 13G/A' and 'Amendment No: 5' sections.
Who is the reporting person in this filing?
The reporting person is BlackRock, Inc., as clearly identified under '(1)Names of reporting persons. BlackRock, Inc.'.
What is the subject company whose securities are being reported?
The subject company is CYTOKINETICS INC, as indicated by 'Name of Issuer) CYTOKINETICS INC'.
What is the CUSIP number for the securities reported?
The CUSIP number for the Common Stock of CYTOKINETICS INC is 23282W605, as listed under '(CUSIP Number) 23282W605'.
What was the date of the event that required this filing?
The date of the event which required this filing was December 31, 2023, as stated under '(Date of Event Which Requires Filing of this Statement) December 31, 2023'.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 22, 2024 regarding CYTOKINETICS INC (CYTK).